Nektar Therapeutics NKTR

NAS: NKTR | ISIN: US6402681083 30/04/2025

0,796 USD (+7,40%)

(+7,40%) 30/04/2025

Grafiek Nektar Therapeutics

Grafiek Nektar Therapeutics

1 dag1d 7,40%
1 week1w 7,75%
1 maand1m 24,82%
3 maanden3m -1,66%
6 maanden6m -35,33%
1 jaar1j -51,79%
5 jaar5j -95,59%

Nektar Therapeutics in het nieuws

Toon enkel gratis nieuws

20 maart 2025 · Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference · Persbericht

12 maart 2025 · Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results · Persbericht

6 maart 2025 · Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets · Persbericht

3 september 2024 · Nektar Management to Present at Upcoming Investor Conferences · Persbericht

8 augustus 2024 · Nektar Therapeutics Reports Second Quarter 2024 Financial Results · Persbericht

2 augustus 2024 · Nektar to Announce Financial Results for the Second Quarter 2024 on Thursday, August 8, 2024, After Close of U.S.-Based Financial Markets · Persbericht

12 juni 2024 · Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024 · Persbericht

31 mei 2024 · Nektar Management to Present at Upcoming Investor Conferences · Persbericht

9 mei 2024 · Nektar Therapeutics Reports First Quarter 2024 Financial Results · Persbericht

3 mei 2024 · Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets · Persbericht

Profiel Nektar Therapeutics

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: www.nektar.com

Hoofdzetel: San Francisco, California Verenigde Staten

CEO: Howard Robin

Werknemers: 820

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe